🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ByTheNumbers: Check out highlights from our Q2 2024 #earnings report: msd.gl/3StfddW

Rob Davis, chairman and CEO, on our Q2 2024 #earnings: msd.gl/3StfddW

Today, we announced that we’ve expanded our global development and commercialization agreement with Daiichi Sankyo. Read more here: msd.gl/4fvfUNR

Today, we announced the acquisition of a novel investigational bispecific antibody from Curon Biopharma. Learn how this further expands and diversifies our growing pipeline, with potential applications in B-cell malignancies and autoimmune diseases: msd.gl/4dj9EY0

Today, we announced the completion of our acquisition of a novel investigational bispecific antibody from Curon Biopharmaceutical offering applications in B-cell malignancies and autoimmune diseases and further broadening our pipeline. Read more: msd.gl/4epGBCK

Today, we shared positive results from our late-stage clinical program in respiratory syncytial virus (#RSV) disease. Learn more here: msd.gl/48grqJF

Today, we announced an agreement to acquire Modifi Bio and the company’s preclinical compounds designed to exploit DNA repair defects in difficult to treat forms of #cancer.

Our Q3 2024 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/3AmgUUG

#ByTheNumbers: Check out highlights from our Q3 2024 #earnings report: msd.gl/3AmgUUG

Rob Davis, chairman and CEO, on our Q3 2024 #earnings: msd.gl/3AmgUUG

Today we announced an exclusive global license to develop, manufacture and commercialize a novel investigational bispecific antibody from LaNova Medicines Ltd. Learn more: msd.gl/40KiGtC

Today we announced an exclusive global license to develop, manufacture and commercialize an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma. Learn more: msd.gl/4gG12Ma

Learn more about our latest news: msd.gl/3ZT2m82

Our Q4 and full-year 2024 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/40JwsuT

#ByTheNumbers: Check out highlights from our Q4 and full-year 2024 #earnings report: msd.gl/40JwsuT

Rob Davis, chairman and CEO, on our Q4 and full-year 2024 #earnings: msd.gl/40JwsuT

Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Learn more: msd.gl/4c1Fh8I

Our Q1 2025 #earnings results are live. Check out our full financial summary and key highlights: msd.gl/3RwURj9

#ByTheNumbers: Check out highlights from our Q1 2025 #earnings report: msd.gl/3RwURj9

Rob Davis, chairman and CEO, on our Q1 2025 #earnings: msd.gl/3RwURj9